Immunome, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
IMNM Nasdaq 2830 immunome.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Immunome, Inc.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 8th, 2026 2:05 pm
Jim Cramer on Immunome: “If You Want to Speculate on It, Fine” - Jan 8th, 2026 5:45 am
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference - Jan 6th, 2026 6:00 am
Immunome Chairman Acquires 5.8% More Stock - Dec 20th, 2025 6:11 am
Immunome Announces Pricing of Public Offering of Common Stock - Dec 16th, 2025 6:16 pm
Immunome (IMNM) Valuation After Breakthrough Phase 3 RINGSIDE Results and Planned FDA New Drug Application - Dec 16th, 2025 6:08 am
Immunome seeks GSI inhibitor market entry on Phase III desmoid tumour win - Dec 16th, 2025 5:26 am
Why Immunome Stock Surged Today - Dec 15th, 2025 4:03 pm
Immunome, A Top 3% Stock, Just Delivered A 'Knockout' To Merck KGaA - Dec 15th, 2025 2:29 pm
Immunome Announces Proposed Public Offering of Common Stock - Dec 15th, 2025 2:01 pm
Sector Update: Health Care Stocks Rise in Afternoon Trading - Dec 15th, 2025 11:47 am
Top Midday Gainers - Dec 15th, 2025 10:28 am
Traders Eye Upcoming Economic Data as US Equity Futures Gain Pre-Bell - Dec 15th, 2025 6:53 am
Immunome Says Phase 3 Trial for Varegacestat in Patients with Desmoid Tumors Meets Primary and Secondary Endpoints - Dec 15th, 2025 5:57 am
Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Dec 15th, 2025 5:00 am
Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Dec 14th, 2025 2:00 pm
Immunome to Present at Upcoming Investor Conferences - Nov 25th, 2025 6:00 am
Insider Stock Buying Reaches US$3.74m On Immunome - Nov 7th, 2025 3:15 am
Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update - Nov 6th, 2025 2:05 pm
Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference - Oct 31st, 2025 9:51 am